Clinical Trials Using Aspirin
Clinical trials are research studies that involve people. The clinical trials on this list are studying Aspirin. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Pembrolizumab, Ipilimumab, and Aspirin in Treating Patients with Melanoma That Is Metastatic or Cannot Be Removed by Surgery
This phase II trial studies how well pembrolizumab, ipilimumab, and aspirin work in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Aspirin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab, ipilimumab, and aspirin may work better in treating patients with melanoma.
Location: UCSF Medical Center-Mount Zion, San Francisco, California
Pembrolizumab, Aspirin, and Clopidogrel Bisulfate in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This randomized phase I trial studies how well pembrolizumab, aspirin, and clopidogrel bisulfate work in treating patients with head and neck squamous cell carcinoma that has come back or that has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Aspirin and clopidogrel bisulfate are a type of drug called anti-platelets that help prevent blood clots. Giving pembrolizumab, aspirin, and clopidogrel bisulfate together may work better in treating patients with head and neck squamous cell carcinoma.
Location: Medical University of South Carolina, Charleston, South Carolina
Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers
We hypothesize through this randomized, placebo-controlled adjuvant study, that Aspirin in patients with dukes C or high risk dukes B colorectal cancer (ASCOLT) can improve survival in this patient population over placebo control. If indeed found to be beneficial, because aspirin is cheap and easy to administer, it will positively impact the lives of many individuals in Asia and globally. STUDY OBJECTIVE To assess the effectiveness of Aspirin against placebo control in patients with dukes C or high risk dukes B colorectal cancer in terms of Disease Free Survival (DFS) and Overall Survival (OS) Primary endpoints - DFS among all eligible subjects (high risk Dukes B colon cancer, Dukes C colon cancer and rectal cancer patient sub-groups); - DFS among patients with colon cancer (high-risk Dukes B and Dukes C colon cancer). Secondary endpoints - Overall survival (OS) over 5 years - DFS and OS in - Chinese, Malay, Indian and other ethnic groups - Resected high risk Dukes B colon cancer, Dukes C colon cancer and rectal cancer sub-groups, individually - Compliant versus non-compliant subjects - PIK3CA mutated tumors (where samples are available)
Location: See Clinical Trials.gov
Aspirin and Rintatolimod with or without Interferon-alpha 2b in Treating Patients with Prostate Cancer Before Surgery
This phase II trial studies how well aspirin and rintatolimod with or without interferon-alpha 2b work in treating patients with prostate cancer before surgery. Aspirin may help to keep the prostate cancer from coming back. Rintatolimod may stimulate the immune system and interfere with the ability of tumor cells to grow and spread. Interferon-alpha 2b may improve the body’s natural response to infections and may slow tumor growth. It is not yet known how well rintatolimod, aspirin, and interferon-alpha 2b work in treating patients with prostate cancer undergoing surgery.
Location: Roswell Park Cancer Institute, Buffalo, New York
Low-Dose Aspirin in Decreasing Inflammation in Patients Undergoing Gynecologic Surgery
This early phase I trial studies how well low-dose aspirin works in decreasing inflammation in patients undergoing gynecologic surgery that includes removal of their fallopian tube. Fallopian tube is a slender tube through which eggs pass from an ovary to the uterus. Low-dose aspirin may decrease inflammation in the fallopian tubes and may provide new information on ovarian cancer prevention that could benefit other patients in the future.
Location: Stephenson Cancer Center, Oklahoma City, Oklahoma
Aspirin in Preventing Recurrence of Cancer in Patients with Node Positive or High Risk Node Negative, HER2 Negative Breast Cancer after Chemotherapy, Surgery, and / or Radiation Therapy
This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with node positive or high risk node negative, human epidermal growth factor receptor 2 (HER2) negative breast cancer after chemotherapy, surgery, and / or radiation therapy. Aspirin is a drug that reduces pain, fever, inflammation, and blood clotting. It is also being studied in cancer prevention. Giving aspirin may reduce the rate of cancer recurrence in patients with breast cancer.
Location: 1269 locations
Aspirin in Preventing Colorectal Cancer in Patients with Colorectal Adenoma
This randomized phase IIa trial studies how well aspirin works in preventing colorectal cancer in patients with colorectal adenoma. Aspirin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
Location: Vanderbilt University / Ingram Cancer Center, Nashville, Tennessee